Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | SCD | O00767 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.31 |
| ▸ | GPR6 | P46095 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.31 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20367265 | 0.87 | MAP3K5 (0.41) | USP30RIPK1SCDMAP3K5 | |
| SCHEMBL20162149 | 0.81 | MAP3K5 (0.34) | USP30RIPK1KLKB1SCDSMYD3 | |
| SCHEMBL20367179 | 0.79 | MAP3K5 (0.42) | USP30SCDMAP3K5 | |
| SCHEMBL21518083 | 0.77 | OGA (0.37) | USP30RIPK1KLKB1SCDSMYD3 | |
| SCHEMBL20367338 | 0.75 | MAP3K5 (0.41) | SCDMAP3K5 | |
| SCHEMBL20367291 | 0.75 | ESR2 (0.46) | SCDNPC1MAP3K5 | |
| SCHEMBL20162156 | 0.74 | TAS2R8 (0.38) | RIPK1KDM4AKDM5AKDM4CKDM5B | |
| SCHEMBL20367451 | 0.73 | HDAC1 (0.38) | KLKB1SCDGPR6MAP3K5 | |
| SCHEMBL20162136 | 0.72 | HDAC1 (0.41) | NPC1 | |
| SCHEMBL18940460 | 0.70 | KDM4C (0.43) | RBP4KLKB1KDM4AKDM5AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| EP-3323809-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2018-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | NR0B1, NR2E1, NR0B2 | RBP4 4194/4885USP30 3712/4885RIPK1 3470/4885 |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | NR0B1, NR2E1, NR0B2 | RBP4 4194/4885USP30 3712/4885RIPK1 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.